RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Susan B Bressler, Michele Melia, Adam R Glassman, Talat Almukhtar, Lee M Jampol, Michel Shami, Brian B Berger, Neil M Bressler, Diabetic Retinopathy Clinical Research Network, Susan B Bressler, Michele Melia, Adam R Glassman, Talat Almukhtar, Lee M Jampol, Michel Shami, Brian B Berger, Neil M Bressler, Diabetic Retinopathy Clinical Research Network
Abstract
Background: The approach to managing diabetic macular edema in eyes with previous vitrectomy is based on limited evidence. Therefore, an exploratory post hoc assessment of 3-year data from eyes with and without vitrectomy before randomization in a DRCR.net trial that evaluated ranibizumab + prompt or deferred laser for diabetic macular edema is presented.
Methods: Visual acuity and optical coherence tomography outcomes were compared between eyes with and without previous vitrectomy.
Results: At baseline, eyes with previous vitrectomy (n = 25) had longer duration of diabetes, worse visual acuity, less thickened central subfield measurements on optical coherence tomography and were more apt to have worse diabetic retinopathy severity level or previous treatment for macular edema or cataract surgery than eyes without a history of vitrectomy (n = 335). Analyses adjusted for these baseline imbalances did not identify substantial differences between eyes with and without previous vitrectomy at each annual visit through 3 years for the favorable visual acuity, optical coherence tomography central subfield thickness, or volume outcomes, although optical coherence tomography improvement appeared slower in vitrectomy eyes during the first year.
Conclusion: This study provides little evidence that the beneficial clinical outcomes for patients with center-involved diabetic macular edema treated with anti-vascular endothelial growth factor are affected in the long term by previous vitrectomy.
Figures
Source: PubMed